Featured Posts
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs, rapid…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
Search Posts
Op-Eds
Precaution (Of A Sort) Without Principle
Miller and Conko Article in Priorities For Health: Volume 13, Number 3 Published by The American Council…
Op-Eds
Dangerous GM Gets Off Scot-Free
Conko and Miller Op-Ed in The Wall Street Journal Europe<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> …
Op-Eds
Cutting Regulation From the EPA: Gene-splicing Policy Should Be Excised
Miller Op-Ed in The Washington TImes Miller Op-Ed in The Washington Times A persistent criticism of the…
Op-Eds
Plants Are Not Pesticides
Miller Op-Ed in The National Post<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> A New U.S. EPA…
News Release
Public Interest Group Welcomes CDC StarLink Report
Washington, DC, June 14, 2001—The Competitive Enterprise Institute welcomes a report by the Centers for Disease Control that finds…
Op-Eds
The Perils Of Precaution
Miller and Conko Article Published In Policy Review<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> Environmental and public health activists have clashed with scholars…